Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST)

Analysts at Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report issued on Tuesday,Benzinga reports. The brokerage set an “overweight” rating and a $17.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 372.22% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Leerink Partners increased their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Stock Down 0.3 %

NASDAQ AQST opened at $3.60 on Tuesday. Aquestive Therapeutics has a twelve month low of $1.84 and a twelve month high of $6.23. The business has a 50-day moving average price of $4.83 and a 200-day moving average price of $4.06. The firm has a market cap of $328.24 million, a price-to-earnings ratio of -8.00 and a beta of 2.62.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the business posted ($0.03) earnings per share. Research analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp boosted its stake in Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after buying an additional 512,682 shares during the period. Blue Owl Capital Holdings LP lifted its holdings in shares of Aquestive Therapeutics by 30.3% in the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after acquiring an additional 265,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $594,000. Verition Fund Management LLC bought a new position in Aquestive Therapeutics during the 3rd quarter valued at about $995,000. Finally, Wellington Management Group LLP purchased a new stake in Aquestive Therapeutics in the 3rd quarter worth about $922,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.